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A B S T R A C T
Two series of novel pyridoxine-based azaheterocyclic analogs of feruloyl methane (Dehydrozingerone, DZG)
were synthesized, and their biological activity against a panel of tumor and normal cell lines was evaluated in
vitro. The most active compounds possessed expressed cytotoxic activity, which was comparable to cytotoxic
activity of doxorubicin and significantly higher than that of DZG, and a remarkable selectivity for the studied
cancer cell lines as compared to the normal cells. The leading compound and DZG initiated arrest of the cell cycle
in the G2/M phase, preventing normal division and further transition of daughter cells to the G0/G1 phase.
Similar to DZG, but with higher efficiency, the leading compound was able to inhibit migration activity and,
therefore, invasiveness of tumor cells. It also increased concentration of reactive oxygen species in tumor cells,
induced depolarization of mitochondrial membranes and initiated apoptosis accompanied by disruption of in-
tegrity of cytoplasmic cell membranes. By contrast to DZG, the leading compound did not possess antioxidant
properties. The obtained data make the described chemotype a promising starting point for the development of
new anticancer agents.
1. Introduction
Curcumin (diferuloylmethane) (Fig. 1) is a natural product ex-
tracted from Curcuma longa plant with remarkable anti-oxidant, anti-
inflammatory and anti-cancer activities.1 Chemopreventive and growth
inhibitory activities of curcumin against many tumor cell lines, in-
cluding drug-resistant ones, have been reported.2,3 However, the ex-
tensive preclinical and clinical studies have shown that curcumin ex-
hibits poor bioavailability and fast metabolism,4,5 mainly due to
instability of the β-diketone fragment in neutral and basic media or in
the presence of aldo-/keto-reductases in vivo. To address these issues,
several approaches have been considered, including development of
liposomal forms, nanoparticles, phospholipid complexes, and structural
modifications to prepare analogs without the β-diketone moiety. In
particular, asymmetric analogs of curcumin with anti-inflammatory
properties were synthesized.6 Numerous mono-carbonyl analogs of
curcumin have also been obtained to improve stability and pharmaco-
kinetic profile in vivo.7,8 Such analogs have attracted attention for
development of new potential anticancer, antiangiogenic and anti-in-
flammatory agents with enhanced bioactivity and optimized pharma-
cokinetic profile.
One of the most remarkable examples of mono-carbonyl analogs is
feruloyl methane (Dehydrozingerone, DZG), a product of metabolic
degradation of curcumin (Fig. 1). It was demonstrated that DZG is
stable under physiological conditions and possesses expressed anti-
tumor properties.9
It has been shown that DZG has an expressed antioxidant ac-
tivity.9,10 By analogy to curcumin, DZG inhibits formation of con-
jugated dienes, prevents spontaneous lipid peroxidation, and prevents
Fe2+/Fe3+ induced peroxidation.11 DZG also reduces cisplatin-induced
cytotoxicity.9 The mechanism of antitumor action of DZG has been
studied on colon cancer cells. It has been found that DZG blocks the cell
cycle at G2/M stage and increases expression of p21 protein.9 To en-
hance pharmacological properties of DZG, several hybrid molecules of
DZG with other natural pharmacophores have been obtained. Thus,
Tatsuzaki et al. synthesized covalent conjugates of DZG with
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